Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR

被引：0
|
作者：
Junttila, M. R. [1 ]
Warne, R. [1 ]
Repellin, C. [1 ]
Sambucetti, L. [1 ]
Chang, J. [2 ]
Kim, S. [3 ]
Kim, H. Y. [3 ]
Shin, D. G. [3 ]
Park, D. H. [3 ]
Patel, R. [4 ]
Maneval, E. Chow [4 ]
Multani, P. S. [4 ]
Daemen, A. [5 ]
Friedman, L. [6 ]
机构：
[1] ORIC Pharmaceut Inc, Dept Biol, South San Francisco, CA USA
[2] ORIC Pharmaceut Inc, DMPK, South San Francisco, CA USA
[3] Voronoi Inc, Incheon, South Korea
[4] ORIC Pharmaceut Inc, Clin Dev, San Diego, CA USA
[5] ORIC Pharmaceut Inc, Translat Med Dept, South San Francisco, CA USA
[6] ORIC Pharmaceut Inc, Res Dept, South San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2378
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1345P
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A dual and selective small molecule inhibitor of EGFR and PI3 kinase shows promising preclinical activity against KRAS and BRAF mutant colorectal tumors
    Maust, Joel D.
    Ziemke, Elizabeth K.
    Frankowski-McGregor, Christy L.
    Ku, Jun Beom
    Mumby, Rachel
    Hardiman, Karin M.
    Whitehead, Christopher E.
    Sebolt-Leopold, Judith S.
    CANCER RESEARCH, 2017, 77
  • [32] Discovery of a third-generation EGFR inhibitor, which is highly selective and potent against both resistant and activating EGFR mutations for NSCLC therapy
    Bao, Rudi
    Gao, Peng
    Zhang, Fujun
    Tong, Zhaolong
    Yu, Hongping
    Xu, Yaochang
    CANCER RESEARCH, 2016, 76
  • [33] Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease
    Ladduwahetty, Tammy
    Lee, Matthew R.
    Maillard, Michel C.
    Cachope, Roger
    Todd, Daniel
    Barnes, Michael
    Beaumont, Vahri
    Chauhan, Alka
    Gallati, Caroline
    Haughan, Alan F.
    Kempf, Georg
    Luckhurst, Christopher A.
    Matthews, Kim
    McAllister, George
    Mitchell, Philip
    Patel, Hiral
    Rose, Mark
    Saville-Stones, Elizabeth
    Steinbacher, Stefan
    Stott, Andrew J.
    Thatcher, Emma
    Tierney, Jason
    Urbonas, Liudvikas
    Munoz-Sanjuan, Ignacio
    Dominguez, Celia
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (14) : 9819 - 9845
  • [34] Osimertinib, an irreversible mutant selective EGFR tyrosine kinase inhibitor, exerts anti tumor activity in NSCLC harbouring exon 20 insertion mutant-EGFR
    Floc'h, Nicolas
    Ashton, Susan
    Bianco, Ambra
    Colclough, Nicola
    Cross, Darren A. E.
    Cuomo, Maria Emanuela
    Finlay, M. Raymond V.
    Martin, Matthew J.
    Menard, Ludovic
    McKerrecher, Darren
    O'Neill, Daniel J.
    Orme, Jonathan P.
    Staniszewska, Anna D.
    Ward, Richard A.
    Yates, James W. T.
    CANCER RESEARCH, 2017, 77
  • [35] Activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2, in adenocarcinoma of the lung with HER2neu kinase domain mutations
    De Greve, J.
    Teugels, E.
    Geers, C.
    De Mey, J.
    in'tveld, P.
    Decoster, L.
    Taton, M.
    Shahidi, M.
    Galdermans, D.
    Schallier, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 555 - 556
  • [36] TAK-788 is a Novel and Potent Tyrosine Kinase Inhibitor with Selective Activity Against EGFR/HER2
    Chouitar, J.
    Vincent, S.
    Brake, R.
    Li, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S811 - S811
  • [37] Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu
    De Greve, Jacques L.
    Teugels, Erik
    De Mey, Johan
    Geers, Caroline
    Galdermans, Danny
    Decoster, Lore
    In 't Veld, Peter
    Schallier, Denis
    Taton, Martine
    Shahidi, Mehdi
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S307 - S307
  • [38] Identification of STX-241, a CNS-penetrant and mutant-selective EGFR inhibitor with activity on osimertinib-resistant C797x mutations
    Pagliarini, Raymond A.
    Milgram, Benjamin C.
    Borrelli, Deanna R.
    O'Hearn, Erin
    Huff, Michael R.
    Ladd, Brendon
    Brooijmans, Natasja
    Wang, Weixue
    Kuzmic, Petr
    Guzman-Perez, Angel
    Stuart, Darrin D.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [39] Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models
    Sharon L. Longo
    David J. Padalino
    Sandra McGillis
    Kirstin Petersen
    Hartmut Schirok
    Oliver Politz
    Gregory W. Canute
    Dawn E. Post
    Investigational New Drugs, 2012, 30 : 2161 - 2172
  • [40] Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models
    Longo, Sharon L.
    Padalino, David J.
    McGillis, Sandra
    Petersen, Kirstin
    Schirok, Hartmut
    Politz, Oliver
    Canute, Gregory W.
    Post, Dawn E.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (06) : 2161 - 2172
12345